ArticlePharmaceutical research2026
Preparation of SP94-Modified Calcium Phosphate Lipid Nanoparticles Loaded with Bcl-2 siRNA and Doxorubicin and Their Targeted Therapeutic Effect on Hepatocellular Carcinoma.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo improve the targeted therapy of hepatocellular carcinoma (HCC), SP94-modified calcium phosphate lipid nanoparticles loaded with Bcl-2 siRNA and doxorubicin (SP94-LCP/DOX&Bcl-2 siRNA) were prepared.
methodsSP94-LCP/DOX&Bcl-2 siRNA was fabricated via reversed-phase microemulsion. Its physicochemical properties (particle size, zeta potential, morphology), pharmaceutical performance (drug loading, encapsulation efficiency, stability, in vitro release), and in vitro activities (targeting, cytotoxicity, apoptosis, apoptosis-related proteins) were evaluated using HepG2 cells via cellular uptake, wound healing, Hoechst 33,258 staining, MTT, and Western blot assays. In vivo antitumor efficacy was tested in HepG2 xenograft nude mice.
resultsSP94-LCP/DOX&Bcl-2 siRNA had a mean diameter of 130 nm and a zeta potential of 20 mV, showing a spherical morphology with uniform distribution. The encapsulation efficiency of siRNA reached 92% and that of doxorubicin is 81%. It exhibited good stability and a significant sustained-release effect. SP94-LCP/DOX&Bcl-2 siRNA significantly reduced the IC₅₀ values of DOX + Bcl-2siRNA, and enhanced the uptake capacity of HepG2 cells for LCP. It remarkably inhibited the migration ability of HepG2 cells, concomitantly downregulating Bcl-2 and upregulating Bax expression, thereby facilitating apoptotic cell death. SP94-LCP/DOX&Bcl-2 siRNA could better inhibit tumor growth in mice and reduce the toxic and side effects on normal tissues of mice.
conclusionsIn this study, SP94-LCP/DOX&Bcl-2 siRNA was successfully prepared. It exhibited remarkable targeting ability and antitumor activity, significantly enhancing the therapeutic effect of doxorubicin and siRNA on HCC. The construction of this drug delivery system provided a novel strategy for the clinical treatment of HCC.
Indexed as
Identifiers
42115559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.